HOMA-IR and the Matsuda Index as predictors of progression to type 1 diabetes in autoantibody-positive relatives.
HOMA
Insulin resistance
Insulin sensitivity
Progression of type 1 diabetes
Stage 3
Type 1 diabetes
Journal
Diabetologia
ISSN: 1432-0428
Titre abrégé: Diabetologia
Pays: Germany
ID NLM: 0006777
Informations de publication
Date de publication:
02 Nov 2023
02 Nov 2023
Historique:
received:
29
03
2023
accepted:
12
09
2023
medline:
2
11
2023
pubmed:
2
11
2023
entrez:
2
11
2023
Statut:
aheadofprint
Résumé
We assessed whether HOMA-IR and the Matsuda Index are associated with transitions through stages of type 1 diabetes. Autoantibody (AAb)-positive relatives of individuals with type 1 diabetes (n=6256) from the TrialNet Pathway to Prevention were studied. Associations of indicators of insulin resistance (HOMA-IR) and insulin sensitivity (Matsuda Index) with BMI percentile (BMIp) and age were assessed with adjustments for measures of insulin secretion, Index60 and insulinogenic index (IGI). Cox regression was used to determine if tertiles of HOMA-IR and Matsuda Index predicted transitions from Not Staged (<2 AAbs) to Stage 1 (≥2 AAbs and normoglycaemia), from Stage 1 to Stage 2 (≥2 AAbs with dysglycaemia), and progression to Stage 3 (diabetes as defined by WHO/ADA criteria). There were strong associations of HOMA-IR (positive) and Matsuda Index (inverse) with baseline age and BMIp (p<0.0001). After adjustments for Index60, transitioning from Stage 1 to Stage 2 was associated with higher HOMA-IR and lower Matsuda Index (HOMA-IR: HR=1.71, p<0.0001; Matsuda Index, HR=0.40, p<0.0001), as with progressing from Stages 1 or 2 to Stage 3 (HOMA-IR: HR=1.98, p<0.0001; Matsuda Index: HR=0.46, p<0.0001). Without adjustments, associations of progression to Stage 3 were inverse for HOMA-IR and positive for Matsuda Index, opposite in directionality with adjustments. When IGI was used in place of Index60, the findings were similar. Progression to Stages 2 and 3 of type 1 diabetes increases with HOMA-IR and decreases with the Matsuda Index after adjustments for insulin secretion. Indicators of insulin secretion appear helpful for interpreting associations of progression to type 1 diabetes with HOMA-IR or the Matsuda Index in AAb-positive relatives.
Identifiants
pubmed: 37914981
doi: 10.1007/s00125-023-06034-y
pii: 10.1007/s00125-023-06034-y
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Juvenile Diabetes Research Foundation International
ID : Dr. Petrelli is supported by the Juvenile Diabetes
Informations de copyright
© 2023. The Author(s).
Références
American Diabetes Association (2014) Diagnosis and classification of diabetes mellitus. Diabetes Care 37(Suppl 1):S81-90
doi: 10.2337/dc14-S081
Leslie RD, Palmer J, Schloot NC, Lernmark A (2016) Diabetes at the crossroads: relevance of disease classification to pathophysiology and treatment. Diabetologia 59(1):13–20. https://doi.org/10.1007/s00125-015-3789-z
doi: 10.1007/s00125-015-3789-z
pubmed: 26498592
Velloso LA, Eizirik DL, Cnop M (2013) Type 2 diabetes mellitus–an autoimmune disease? Nat Rev Endocrinol 9(12):750–5. https://doi.org/10.1038/nrendo.2013.131
doi: 10.1038/nrendo.2013.131
pubmed: 23835371
Pearson ER (2019) Type 2 diabetes: a multifaceted disease. Diabetologia 62(7):1107–12. https://doi.org/10.1007/s00125-019-4909-y
doi: 10.1007/s00125-019-4909-y
pubmed: 31161345
pmcid: 6560016
de Candia P, Prattichizzo F, Garavelli S et al (2019) Type 2 diabetes: how much of an autoimmune disease? Front Endocrinol (Lausanne) 10:451. https://doi.org/10.3389/fendo.2019.00451
doi: 10.3389/fendo.2019.00451
pubmed: 31333589
Brooks-Worrell BM, Palmer JP (2019) Setting the stage for islet autoimmunity in type 2 diabetes: obesity-associated chronic systemic inflammation and endoplasmic reticulum (ER) stress. Diabetes Care 42(12):2338–46. https://doi.org/10.2337/dc19-0475
doi: 10.2337/dc19-0475
pubmed: 31748213
pmcid: 7364670
Insel RA, Dunne JL, Atkinson MA et al (2015) Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care 38(10):1964–74. https://doi.org/10.2337/dc15-1419
doi: 10.2337/dc15-1419
pubmed: 26404926
pmcid: 5321245
Buzzetti R, Zampetti S, Pozzilli P (2020) Impact of obesity on the increasing incidence of type 1 diabetes. Diabetes Obes Metab 22(7):1009–13. https://doi.org/10.1111/dom.14022
doi: 10.1111/dom.14022
pubmed: 32157790
Liu LL, Lawrence JM, Davis C et al (2010) Prevalence of overweight and obesity in youth with diabetes in USA: the SEARCH for Diabetes in Youth study. Pediatr Diabetes 11(1):4–11. https://doi.org/10.1111/j.1399-5448.2009.00519.x
doi: 10.1111/j.1399-5448.2009.00519.x
pubmed: 19473302
DuBose SN, Hermann JM, Tamborlane WV et al (2015) Obesity in youth with type 1 diabetes in Germany, Austria, and the United States. J Pediatr 167(3):627–32.e1-4. https://doi.org/10.1016/j.jpeds.2015.05.046
doi: 10.1016/j.jpeds.2015.05.046
pubmed: 26164381
Ferrara CT, Geyer SM, Liu YF et al (2017) Excess BMI in childhood: a modifiable risk factor for type 1 diabetes development? Diabetes Care 40(5):698–701. https://doi.org/10.2337/dc16-2331
doi: 10.2337/dc16-2331
pubmed: 28202550
pmcid: 5399656
Libman IM, Pietropaolo M, Arslanian SA, LaPorte RE, Becker DJ (2003) Changing prevalence of overweight children and adolescents at onset of insulin-treated diabetes. Diabetes Care 26(10):2871–5. https://doi.org/10.2337/diacare.26.10.2871
doi: 10.2337/diacare.26.10.2871
pubmed: 14514594
Zucker I, Zloof Y, Bardugo A et al (2022) Obesity in late adolescence and incident type 1 diabetes in young adulthood. Diabetologia. https://doi.org/10.2337/db22-1263-P
doi: 10.2337/db22-1263-P
pubmed: 35665825
Hypponen E, Virtanen SM, Kenward MG, Knip M, Akerblom HK, Childhood Diabetes in Finland Study G (2000) Obesity, increased linear growth, and risk of type 1 diabetes in children. Diabetes Care 23(12):1755–60. https://doi.org/10.2337/diacare.23.12.1755
doi: 10.2337/diacare.23.12.1755
pubmed: 11128347
Matsuda M, DeFronzo RA (1999) Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22(9):1462–70. https://doi.org/10.2337/diacare.22.9.1462
doi: 10.2337/diacare.22.9.1462
pubmed: 10480510
Song Y, Manson JE, Tinker L et al (2007) Insulin sensitivity and insulin secretion determined by homeostasis model assessment and risk of diabetes in a multiethnic cohort of women: the Women’s Health Initiative Observational Study. Diabetes Care 30(7):1747–52. https://doi.org/10.2337/dc07-0358
doi: 10.2337/dc07-0358
pubmed: 17468352
Meah FA, DiMeglio LA, Greenbaum CJ et al (2016) The relationship between BMI and insulin resistance and progression from single to multiple autoantibody positivity and type 1 diabetes among TrialNet Pathway to Prevention participants. Diabetologia 59(6):1186–95. https://doi.org/10.1007/s00125-016-3924-5
doi: 10.1007/s00125-016-3924-5
pubmed: 26995649
pmcid: 5081287
Ma X, Becker D, Arena VC, Vicini P, Greenbaum C (2009) The effect of age on insulin sensitivity and insulin secretion in first-degree relatives of type 1 diabetic patients: a population analysis. J Clin Endocrinol Metab 94(7):2446–51. https://doi.org/10.1210/jc.2008-2687
doi: 10.1210/jc.2008-2687
pubmed: 19401372
pmcid: 2708949
Stadler M, Pacini G, Petrie J, Luger A, Anderwald C, Investigators R (2009) Beta cell (dys)function in non-diabetic offspring of diabetic patients. Diabetologia 52(11):2435–44. https://doi.org/10.1007/s00125-009-1520-7
doi: 10.1007/s00125-009-1520-7
pubmed: 19756484
Yeckel CW, Weiss R, Dziura J et al (2004) Validation of insulin sensitivity indices from oral glucose tolerance test parameters in obese children and adolescents. J Clin Endocrinol Metab 89(3):1096–101. https://doi.org/10.1210/jc.2003-031503
doi: 10.1210/jc.2003-031503
pubmed: 15001593
Nathan BM, Boulware D, Geyer S et al (2017) Dysglycemia and index60 as prediagnostic end points for type 1 diabetes prevention trials. Diabetes Care 40(11):1494–9. https://doi.org/10.2337/dc17-0916
doi: 10.2337/dc17-0916
pubmed: 28860125
pmcid: 5652585
Nathan BM, Redondo MJ, Ismail H et al (2022) Index60 identifies individuals at appreciable risk for stage 3 among an autoantibody-positive population with normal 2-hour glucose levels: implications for current staging criteria of type 1 diabetes. Diabetes Care 45(2):311–8. https://doi.org/10.2337/dc21-0944
doi: 10.2337/dc21-0944
pubmed: 34853027
Skyler JS, Greenbaum CJ, Lachin JM et al (2008) Type 1 diabetes TrialNet–an international collaborative clinical trials network. Ann N Y Acad Sci 1150:14–24. https://doi.org/10.1196/annals.1447.054
doi: 10.1196/annals.1447.054
pubmed: 19120262
pmcid: 2918900
Mahon JL, Sosenko JM, Rafkin-Mervis L et al (2009) The TrialNet natural history study of the development of type 1 diabetes: objectives, design, and initial results. Pediatr Diabetes 10(2):97–104. https://doi.org/10.1111/j.1399-5448.2008.00464.x
doi: 10.1111/j.1399-5448.2008.00464.x
pubmed: 18823409
Deligne C, You S, Mallone R (2022) Personalized immunotherapies for type 1 diabetes: who, what, when, and how? J Pers Med 12(4):542. https://doi.org/10.3390/jpm12040542
doi: 10.3390/jpm12040542
pubmed: 35455658
pmcid: 9031881
Bechi Genzano C, Bezzecchi E, Carnovale D et al (2022) Combined unsupervised and semi-automated supervised analysis of flow cytometry data reveals cellular fingerprint associated with newly diagnosed pediatric type 1 diabetes. Front Immunol 13:1026416. https://doi.org/10.3389/fimmu.2022.1026416
doi: 10.3389/fimmu.2022.1026416
pubmed: 36389771
pmcid: 9647173
American Diabetes A (2021) 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2021. Diabetes Care 44(Suppl 1):S15–S33. https://doi.org/10.2337/dc21-S002
doi: 10.2337/dc21-S002
Dayan CM, Korah M, Tatovic D, Bundy BN, Herold KC (2019) Changing the landscape for type 1 diabetes: the first step to prevention. Lancet 394(10205):1286–96. https://doi.org/10.1016/S0140-6736(19)32127-0
doi: 10.1016/S0140-6736(19)32127-0
pubmed: 31533907
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28(7):412–9. https://doi.org/10.1007/BF00280883
doi: 10.1007/BF00280883
pubmed: 3899825
Sosenko JM, Skyler JS, DiMeglio LA et al (2015) A new approach for diagnosing type 1 diabetes in autoantibody-positive individuals based on prediction and natural history. Diabetes Care 38(2):271–6. https://doi.org/10.2337/dc14-1813
doi: 10.2337/dc14-1813
pubmed: 25519451
Tura A, Kautzky-Willer A, Pacini G (2006) Insulinogenic indices from insulin and C-peptide: comparison of beta-cell function from OGTT and IVGTT. Diabetes Res Clin Pract 72(3):298–301. https://doi.org/10.1016/j.diabres.2005.10.005
doi: 10.1016/j.diabres.2005.10.005
pubmed: 16325298
Henriquez S, Jara N, Bunout D et al (2013) Variability of formulas to assess insulin sensitivity and their association with the Matsuda index. Nutr Hosp 28(5):1594–8. https://doi.org/10.3305/nh.2013.28.5.6512
doi: 10.3305/nh.2013.28.5.6512
pubmed: 24160221
Lewandowski KC, Plusajska J, Horzelski W, Bieniek E, Lewinski A (2018) Limitations of insulin resistance assessment in polycystic ovary syndrome. Endocr Connect 7(3):403–12. https://doi.org/10.1530/EC-18-0021
doi: 10.1530/EC-18-0021
pubmed: 29436386
pmcid: 5834769
DeFronzo RA, Tobin JD, Andres R (1979) Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 237(3):E214-23
pubmed: 382871
Bergman BC, Howard D, Schauer IE et al (2013) The importance of palmitoleic acid to adipocyte insulin resistance and whole-body insulin sensitivity in type 1 diabetes. J Clin Endocrinol Metab 98(1):E40-50. https://doi.org/10.1210/jc.2012-2892
doi: 10.1210/jc.2012-2892
pubmed: 23150678
Bergman BC, Howard D, Schauer IE et al (2012) Features of hepatic and skeletal muscle insulin resistance unique to type 1 diabetes. J Clin Endocrinol Metab 97(5):1663–72. https://doi.org/10.1210/jc.2011-3172
doi: 10.1210/jc.2011-3172
pubmed: 22362823
pmcid: 3339891
Perseghin G, Lattuada G, Danna M et al (2003) Insulin resistance, intramyocellular lipid content, and plasma adiponectin in patients with type 1 diabetes. Am J Physiol Endocrinol Metab 285(6):E1174-81. https://doi.org/10.1152/ajpendo.00279.2003
doi: 10.1152/ajpendo.00279.2003
pubmed: 12933352
Perseghin G, Lattuada G, De Cobelli F et al (2005) Reduced intrahepatic fat content is associated with increased whole-body lipid oxidation in patients with type 1 diabetes. Diabetologia 48(12):2615–21. https://doi.org/10.1007/s00125-005-0014-5
doi: 10.1007/s00125-005-0014-5
pubmed: 16261312
Donga E, Dekkers OM, Corssmit EP, Romijn JA (2015) Insulin resistance in patients with type 1 diabetes assessed by glucose clamp studies: systematic review and meta-analysis. Eur J Endocrinol 173(1):101–9. https://doi.org/10.1530/EJE-14-0911
doi: 10.1530/EJE-14-0911
pubmed: 25899581
Fourlanos S, Narendran P, Byrnes GB, Colman PG, Harrison LC (2004) Insulin resistance is a risk factor for progression to type 1 diabetes. Diabetologia 47(10):1661–7. https://doi.org/10.1007/s00125-004-1507-3
doi: 10.1007/s00125-004-1507-3
pubmed: 15480539
Galderisi A, Moran A, Evans-Molina C et al (2021) Early impairment of insulin sensitivity, beta-cell responsiveness, and insulin clearance in youth with stage 1 type 1 diabetes. J Clin Endocrinol Metab 106(9):2660–9. https://doi.org/10.1210/clinem/dgab344
doi: 10.1210/clinem/dgab344
pubmed: 34000022
pmcid: 8372628
Siljander HT, Hermann R, Hekkala A et al (2013) Insulin secretion and sensitivity in the prediction of type 1 diabetes in children with advanced beta-cell autoimmunity. Eur J Endocrinol 169(4):479–85. https://doi.org/10.1530/EJE-13-0206
doi: 10.1530/EJE-13-0206
pubmed: 23904276
Bingley PJ, Mahon JL, Gale EA, European Nicotinamide Diabetes Intervention Trial G (2008) Insulin resistance and progression to type 1 diabetes in the European Nicotinamide Diabetes Intervention Trial (ENDIT). Diabetes Care 31(1):146–50. https://doi.org/10.2337/dc07-0103
doi: 10.2337/dc07-0103
pubmed: 17959864
Hawa MI, Bonfanti R, Valeri C, Delli Castelli M, Beyan H, Leslie RD (2005) No evidence for genetically determined alteration in insulin secretion or sensitivity predisposing to type 1 diabetes: a study of identical twins. Diabetes Care 28(6):1415–8. https://doi.org/10.2337/diacare.28.6.1415
doi: 10.2337/diacare.28.6.1415
pubmed: 15920061
Wilkin TJ (2001) The accelerator hypothesis: weight gain as the missing link between type I and type II diabetes. Diabetologia 44(7):914–22. https://doi.org/10.1007/s001250100548
doi: 10.1007/s001250100548
pubmed: 11508279
Sosenko JM, Palmer JP, Greenbaum CJ et al (2006) Patterns of metabolic progression to type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care 29(3):643–9. https://doi.org/10.2337/diacare.29.03.06.dc05-1006
doi: 10.2337/diacare.29.03.06.dc05-1006
pubmed: 16505520
Bingley PJ (1996) Interactions of age, islet cell antibodies, insulin autoantibodies, and first-phase insulin response in predicting risk of progression to IDDM in ICA+ relatives: the ICARUS data set. Islet Cell Antibody Register Users Study. Diabetes 45(12):1720–8. https://doi.org/10.2337/diab.45.12.1720
doi: 10.2337/diab.45.12.1720
pubmed: 8922357
Ismail HM, Becker DJ, Libman I et al (2020) Early and late C-peptide responses during oral glucose tolerance testing are oppositely predictive of type 1 diabetes in autoantibody-positive individuals. Diabetes Obes Metab 22(6):997–1000. https://doi.org/10.1111/dom.13982
doi: 10.1111/dom.13982
pubmed: 32003110
pmcid: 7341484
Petrelli A, Giovenzana A, Insalaco V, Phillips BE, Pietropaolo M, Giannoukakis N (2021) Autoimmune inflammation and insulin resistance: hallmarks so far and yet so close to explain diabetes endotypes. Curr Diab Rep 21(12):54. https://doi.org/10.1007/s11892-021-01430-3
doi: 10.1007/s11892-021-01430-3
pubmed: 34902055
pmcid: 8668851
Kim SH, Park MJ (2017) Effects of growth hormone on glucose metabolism and insulin resistance in human. Ann Pediatr Endocrinol Metab 22(3):145–52. https://doi.org/10.6065/apem.2017.22.3.145
doi: 10.6065/apem.2017.22.3.145
pubmed: 29025199
pmcid: 5642081
Bergman RN, Ader M, Huecking K, Van Citters G (2002) Accurate assessment of beta-cell function: the hyperbolic correction. Diabetes 51(Suppl 1):S212-20. https://doi.org/10.2337/diabetes.51.2007.s212
doi: 10.2337/diabetes.51.2007.s212
pubmed: 11815482
Lorenzo C, Wagenknecht LE, Rewers MJ et al (2010) Disposition index, glucose effectiveness, and conversion to type 2 diabetes: the Insulin Resistance Atherosclerosis Study (IRAS). Diabetes Care 33(9):2098–103. https://doi.org/10.2337/dc10-0165
doi: 10.2337/dc10-0165
pubmed: 20805282
pmcid: 2928371